Axsome Therapeutics Reaches Agreement to Dismiss Sunosi (Solriamfetol) Patent Litigation with Sandoz Inc. Page 1

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of disorders of the central nervous system, today announced that it has reached an agreement with Sandoz Inc. (Sandoz) to dismiss a patent lawsuit related to Axsome’s product Sunosi (solriamfetol). The lawsuit, pending in the United States District Court for the District of New Jersey, arose following Sandoz’s filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market a generic equivalent of Sunosi in the United States. Sandoz has withdrawn its ANDA for a generic equivalent of Sunosi and, as a result, the lawsuit has been dismissed without prejudice.

Information about Axsome Therapeutics, Inc.